CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

18F-GP1 PET CTWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D002546 Ischemic Attack, Transient NIH 0.71
D007238 Infarction NIH 0.38
D009203 Myocardial Ischemia NIH 0.29
D011655 Pulmonary Embolism NIH 0.28
D004617 Embolism NIH 0.27
D013927 Thrombosis NIH 0.22

Correlated HPO Terms (3)

Name (Synonyms) Correlation
HP:0002326 Transient ischemic attack HPO 0.71
HP:0001658 Myocardial infarction HPO 0.29
HP:0002204 Pulmonary embolism HPO 0.28

There is one clinical trial.

Clinical Trials

1 In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer

To date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis. The investigators aim to further the mechanistic understanding of atherothrombosis by studying the activation of glycoprotein IIb/IIIa receptors in cardiovascular thrombus using the novel platelet radiotracer (18F-GP1). Binding of 18F-GP1 to activated platelets in venous and arterial thrombi has already been demonstrated in pre-clinical studies and a phase 1 trial in man. If successful, this study would define the role of the glycoprotein IIb/IIIa receptor within in vivo thrombosis across a range of cardiovascular diseases.

NCT03943966 Thrombosis Atherothrombosis Myocardial Infarction STEMI NSTEMI - Non-ST Segment Elevation MI DVT Pulmonary Embolism Stroke Transient Ischemic Attack Prosthetic Valve Thrombosis PET Diagnostic Test: 18F-GP1 PET CT
MeSH:Pulmonary Embolism Ischemic Attack, Transient Myocardial Infarction Thrombosis Embolism Infarction
HPO:Myocardial infarction Pulmonary embolism Transient ischemic attack

Primary Outcomes

Description: Expression of the glycoprotein IIb/IIIa receptor (assessed by SUV) within thrombus in the arterial and venous circulation.

Measure: Ratio of 18F-GP1 standardised uptake values (SUV's) in thrombus compared with the SUVs recorded in the blood pool.

Time: 6 months from end of recruitment

Secondary Outcomes

Description: Expression of the glycoprotein IIb/IIIa receptor (assessed by SUV) within thrombus in the arterial and venous circulation in all 5 disease states

Measure: Ratio of 18F-GP1 standardised uptake values (SUV's) in thrombus formed in each of the 5 disease states.

Time: 6 months from end of recruitment

Related HPO nodes (Using clinical trials)

HP:0001658: Myocardial infarction
Genes 79
MYH9 JAK2 IL12A CYP27A1 HLA-B BSCL2 LIMK1 RFC2 LDLR LPL RAF1 MEFV SH2B3 ABCA1 WRN GTF2I SCNN1A TBL2 CYP27A1 HLA-B MEFV ABCG8 ELN BRAF C4A IL12A-AS1 CEP19 CAV1 IKZF1 UBAC2 MLX THOC2 CTNNB1 PTPN11 SCNN1G MEF2A IL10 CLIP2 IL12B ABCC6 MYH9 ABCA1 LDLRAP1 GLA STAT4 SH2B3 CFTR SLC2A10 IL23R CBS ERAP1 BAZ1B LMNA PCSK9 CCR1 BRAF FOS APOB KLRC4 JAK2 AGPAT2 TET2 LRP6 BCHE ABCG5 TLR4 HLA-B DYRK1B SCNN1B GTF2IRD1 TP53 PPARG CAVIN1 MPL ENPP1 PIGA FAS CALR HGD
Protein Mutations 13
A1166C C344T C807T G1051A G20210A G3514C G98T I843S L33P M235T Q192R Q222R V34L
SNP 11
rs10153820 rs16969968 rs1761667 rs4244285 rs4986893 rs6434222 rs6971 rs7586970 rs7903146 rs8069645 rs8176528
HP:0002204: Pulmonary embolism
Genes 43
HABP2 IL23R IL12A SERPINC1 HLA-B CBS ERAP1 KCNJ5 PROS1 SMAD4 GNAQ CCR1 PROC ACVRL1 F2 PROC PTEN SERPINC1 MTHFR KLRC4 ENG CD55 GDF2 AKT1 TET2 PLP1 MEFV C4A IL12A-AS1 MPL AGGF1 UBAC2 TLR4 PROS1 PROC IL10 F13A1 PIGA FAS GNAQ JAK2 PROS1 STAT4
Protein Mutations 2
G20210A G21210A
SNP 0
HP:0002326: Transient ischemic attack
Genes 53
SMARCAL1 ACTA2 ENG ENG JAK2 SMAD4 PRKG1 KRAS GDF2 SMAD3 MFAP5 TGFBR3 NR2F2 LMNA LOX GATA6 TGFBR2 ELN THPO GLA MYLK SH2B3 GATA4 TGFB3 ANGPTL6 GLA SMAD4 ACVRL1 MPL ENG MAT2A JAK2 FBN1 ZMPSTE24 ACVRL1 COL3A1 TET2 TGFBR1 TGFB2 SON ACTG1 TP53 FOXE3 THSD1 ACTB MPL HTRA1 PIGA MYH11 CALR COL3A1 MYBPC3 CRELD1
Protein Mutations 0
SNP 0